Home > Compound List > Product Information
CPNQ_Molecular_structure_CAS_115687-05-3)
Click picture or here to close

CPNQ

Catalog No. C3118 Name Sigma Aldrich
CAS Number 115687-05-3 Website http://www.sigmaaldrich.com
M. F. C20H17ClN4O3 Telephone 1-800-521-8956
M. W. 396.82698 Fax
Purity ≥98% (HPLC) Email
Storage Chembase ID: 153967

SYNONYMS

IUPAC name
5-[4-(4-chlorobenzoyl)piperazin-1-yl]-8-nitroquinoline
IUPAC Traditional name
5-[4-(4-chlorobenzoyl)piperazin-1-yl]-8-nitroquinoline
Synonyms
5-[4-(4-chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline
B2

DATABASE IDS

CAS Number 115687-05-3
MDL Number MFCD02039810

PROPERTIES

GHS Precautionary statements P261-P301 + P310-P305 + P351 + P338
RID/ADR UN 2811 6.1/PG 3
Risk Statements 25-36/37/38
Safety Statements 26-45
Storage Temperature 2-8°C
Hazard Class 6.1
UN Number 2811
Packing Group 3
German water hazard class 3
GHS Pictograms GHS06
GHS Signal Word Danger
GHS Hazard statements H301-H315-H319-H335
European Hazard Symbols Toxic Toxic (T)
MSDS Link Download
Personal Protective Equipment Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
Empirical Formula (Hill Notation) C20H17ClN4O3
Purity ≥98% (HPLC)
Apperance brown solid
Solubility H2O: insoluble <2 mg/mL
Solubility DMSO: >5 mg/mL

DETAILS

Description (English)
Other Notes
Product is air sensitive.
Biochem/physiol Actions
Misfolded proteins accumulate in many neurodegenerative diseases, including huntingtin in Huntington′s disease and alpha-synuclein in Parkinson′s disease. The disease-causing proteins can take various conformations and are prone to aggregate and form larger cytoplasmic or nuclear inclusions. CPNQ (B2) was identified as a compound that promotes inclusion formation in cellular models of both Huntington′s disease and Parkinson′s disease. Despite the aggregate-forming specifics the compound prevents huntingtin-mediated proteasome dysfunction and reduces alpha-synuclein-mediated toxicity. These results demonstrate that compounds that increase inclusion formation may actually lessen cellular pathology in both Huntington′s and Parkinson′s diseases, suggesting a therapeutic approach for neurodegenerative diseases caused by protein misfolding. The ability of B2 to prevent toxicity, despite increasing inclusions, suggests that inclusions are beneficial rather than toxic, which will be further explored as the molecular target and mechanism. CPNQ (B2) is a desirable tool for both Huntington′s and Parkinson′s research.
Description (简体中文)
Other Notes
Product is air sensitive.
Biochem/physiol Actions
Misfolded proteins accumulate in many neurodegenerative diseases, including huntingtin in Huntington′s disease and alpha-synuclein in Parkinson′s disease. The disease-causing proteins can take various conformations and are prone to aggregate and form larger cytoplasmic or nuclear inclusions. CPNQ (B2) was identified as a compound that promotes inclusion formation in cellular models of both Huntington′s disease and Parkinson′s disease. Despite the aggregate-forming specifics the compound prevents huntingtin-mediated proteasome dysfunction and reduces alpha-synuclein-mediated toxicity. These results demonstrate that compounds that increase inclusion formation may actually lessen cellular pathology in both Huntington′s and Parkinson′s diseases, suggesting a therapeutic approach for neurodegenerative diseases caused by protein misfolding. The ability of B2 to prevent toxicity, despite increasing inclusions, suggests that inclusions are beneficial rather than toxic, which will be further explored as the molecular target and mechanism. CPNQ (B2) is a desirable tool for both Huntington′s and Parkinson′s research.

REFERENCES